Conference to Explore Latest Screening Methods and Treatments for Lung Cancer
23rd International Conference on Screening for Lung Cancer To Be Held at The Mount Sinai Medical Center October 22 and 23
The most advanced screening methods and procedures for treating early-stage lung cancer will be explored in-depth on Friday, October 22, and Saturday, October 23, at the 23rd International Conference on Screening for Lung Cancer at The Mount Sinai Medical Center in New York City. More information is available at the website of the International Early Lung Cancer Action Program (I-ELCAP) at http://www.ielcap.org/.
Lung cancer is the leading cancer killer in America, claiming more lives than breast, colon, and prostate cancer combined. Over 160,000 people die of lung cancer in the United States each year, and 85 percent of patients diagnosed with lung cancer die from it within five years. Over 1.2 million people die worldwide each year.
- A highlight of the conference will be on Friday morning (10:45 AM), when Drs. David Yankelevitz and Claudia Henschke of Mount Sinai School of Medicine present research on the use of low-dose CT scans to detect early-stage lung cancer, and how those scans have proven to be useful in detecting other health problems.
Research has shown that when lung cancers are found at the earliest stage and are promptly removed with surgery, patients have a 92 percent chance of being cured, and 85 percent of the patients who were diagnosed with annual CT screening had this curable, early-stage cancer. By contrast, 95 percent of patients who are diagnosed only after they experience symptoms will ultimately die of the disease. Screening with chest x-rays has been found to be much less effective, and typically misses around 85 percent of the early-stage cancers detected by CT scans.
Dr. Henschke will present new research that shows that in addition to being effective at detecting early-stage lung cancer, CT scans using the same radiation doses are also effective at detecting other health issues such as cardiovascular disease and chronic obstructive pulmonary disease.
"Research into ordinal scoring of the visual assessment of coronary artery calcification on low-dose CT scans of the chest confirms that visual assessment provides clinically relevant quantitative information as to cardiovascular death," said Dr. Henschke. "These findings reinforce the multiple uses of annual low-dose CT scans, in addition to being the most effective early-stage lung cancer screening tool."
- The Conference will also feature an update on Friday (9:15 AM) by Dr. Yankelevitz on the Global Alliance for Lung Cancer Research (GALCAR), which is bringing together over 100 hospitals and research institutions from almost every continent to foster international collaboration to see that research innovations are rapidly translated into treatment options for people with or at risk for the disease.
GALCAR will provide a common framework for international lung cancer projects, with emphasis on interdisciplinary and translational initiatives, notably in regard to biosignatures, which have the potential to immediately reduce lung cancer incidence and mortality.
It will build on the existing networks of I-ELCAP, a lung cancer research organization with 60+ sites in 26 states and 8 other countries whose mission is to reduce deaths from lung cancer by early detection and diagnosis through screening by computed tomography, and the International Lung Cancer Consortium (ILCCO), a network of over 40 studies of molecular and genetic epidemiology of lung cancer. Dr. Paolo Boffetta, Deputy Director of the Tisch Cancer Center at Mount Sinai, is co-principal investigator of ILCCO.
GALCAR will also seek to play a leadership role in lung cancer next-generation sequencing (NGS) by developing an integrated, international tissue biobanking strategy for collecting lung cancer tissues; developing a multi-disciplinary platform for integrating epidemiological, clinical, pathological and imaging information; and integrating the knowledge generated by NGS into an open-source, web-based World Atlas of Genetic Alterations in Human Cancer.
- A major component of Saturday’s program (9:15 AM) will discuss ongoing projects to examine lung cancer in people who have never smoked (never-smokers), who globally account for over 300,000 new lung cancer cases each year.
Updates will be presented on studies of never-smokers in Asia, Central Europe and South America; the EDRN-Canary Biomarker program; lung and cardiac diseases in Flight Attendant Medical Research Institute (FAMRI) projects; and genetic susceptibility to lung cancer.
Other sessions at the Conference will discuss the surgical treatment of Stage I lung cancer; advances in radiotherapy; other tobacco-related diseases; genetic alterations in lung cancer; the effects of self-selection in lung cancer screening; lung cancer risk predictions; and the use of CAD in detection of pulmonary malignancies on chest radiographs.
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of few medical schools embedded in a hospital in the United States. It has more than 3,400 faculty in 32 departments and 15 institutes, and ranks among the top 20 medical schools both in National Institute of Health funding and by U.S. News & World Report. The school received the 2009 Spencer Foreman Award for Outstanding Community Service from the Association of American Medical Colleges.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. U.S. News & World Report consistently ranks The Mount Sinai Hospital among the nation's best hospitals based on reputation, patient safety, and other patient-care factors. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 530,000 outpatient visits took place.
For more information, visit www.mountsinai.org. Follow us on Twitter @mountsinainyc.